US20150118701A1 - Enzyme assay with duplicate fluorophores - Google Patents
Enzyme assay with duplicate fluorophores Download PDFInfo
- Publication number
- US20150118701A1 US20150118701A1 US14/523,712 US201414523712A US2015118701A1 US 20150118701 A1 US20150118701 A1 US 20150118701A1 US 201414523712 A US201414523712 A US 201414523712A US 2015118701 A1 US2015118701 A1 US 2015118701A1
- Authority
- US
- United States
- Prior art keywords
- signal
- peptide
- reporter
- cell
- enzyme activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001952 enzyme assay Methods 0.000 title 1
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 125
- 230000007017 scission Effects 0.000 claims abstract description 125
- 210000004027 cell Anatomy 0.000 claims abstract description 90
- 102000004190 Enzymes Human genes 0.000 claims abstract description 65
- 108090000790 Enzymes Proteins 0.000 claims abstract description 65
- 230000000694 effects Effects 0.000 claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 35
- 210000000172 cytosol Anatomy 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims description 60
- 238000003556 assay Methods 0.000 claims description 40
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 36
- 238000004873 anchoring Methods 0.000 claims description 26
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims description 24
- 102000034287 fluorescent proteins Human genes 0.000 claims description 16
- 108091006047 fluorescent proteins Proteins 0.000 claims description 16
- 102000000583 SNARE Proteins Human genes 0.000 claims description 14
- 108010041948 SNARE Proteins Proteins 0.000 claims description 14
- 101710117515 Botulinum neurotoxin type E Proteins 0.000 claims description 13
- 230000003413 degradative effect Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 3
- 108030001720 Bontoxilysin Proteins 0.000 abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 12
- 238000000423 cell based assay Methods 0.000 abstract description 9
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 238000006731 degradation reaction Methods 0.000 abstract description 8
- 230000002255 enzymatic effect Effects 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000008859 change Effects 0.000 abstract description 5
- 239000000975 dye Substances 0.000 description 51
- 229940088598 enzyme Drugs 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 23
- 210000000170 cell membrane Anatomy 0.000 description 18
- 230000005284 excitation Effects 0.000 description 17
- 239000012491 analyte Substances 0.000 description 14
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 12
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 11
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 11
- 238000000295 emission spectrum Methods 0.000 description 11
- 238000000695 excitation spectrum Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- -1 J-Red Proteins 0.000 description 9
- 239000004365 Protease Substances 0.000 description 9
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 9
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 9
- 102000005917 R-SNARE Proteins Human genes 0.000 description 9
- 108010005730 R-SNARE Proteins Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000010606 normalization Methods 0.000 description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 6
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 6
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 5
- 101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 108010021843 fluorescent protein 583 Proteins 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 4
- 229940053031 botulinum toxin Drugs 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108010054624 red fluorescent protein Proteins 0.000 description 4
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 description 3
- 108091005944 Cerulean Proteins 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 241000545067 Venus Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 229910052594 sapphire Inorganic materials 0.000 description 3
- 239000010980 sapphire Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 241000242764 Aequorea victoria Species 0.000 description 2
- 241000579895 Chlorostilbon Species 0.000 description 2
- 108091005943 CyPet Proteins 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000010976 emerald Substances 0.000 description 2
- 229910052876 emerald Inorganic materials 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000026792 palmitoylation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- WKBPZYKAUNRMKP-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)pentyl]1,2,4-triazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1C(CCC)CN1C=NC=N1 WKBPZYKAUNRMKP-UHFFFAOYSA-N 0.000 description 1
- QEIQEORTEYHSJH-UHFFFAOYSA-N Armin Natural products C1=CC(=O)OC2=C(O)C(OCC(CCO)C)=CC=C21 QEIQEORTEYHSJH-UHFFFAOYSA-N 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 description 1
- 101100457021 Caenorhabditis elegans mag-1 gene Proteins 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 101000933563 Clostridium botulinum Botulinum neurotoxin type G Proteins 0.000 description 1
- 101000985020 Clostridium botulinum D phage Botulinum neurotoxin type D Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108091005947 EBFP2 Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101100067996 Mus musculus Gbp1 gene Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000036859 Zinc-dependent proteases Human genes 0.000 description 1
- 108091006973 Zinc-dependent proteases Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108091005706 peripheral membrane proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011031 topaz Substances 0.000 description 1
- 229910052853 topaz Inorganic materials 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
Definitions
- the field of the invention is protease assays, especially those related to Clostridium botulinum neurotoxins.
- Botulinum neurotoxins are produced by Clostridium botulinum, and are among the most potent toxins known. These toxins are a well-recognized source of food poisoning, often resulting in serious harm or even death of the victims.
- BoNT/A-G structurally similar botulinum neurotoxins or serotypes
- BoNT/H structurally similar botulinum neurotoxins or serotypes
- the heavy chain mediates toxin entry into a target cell through receptor-mediated endocytosis.
- the light chain is translocated from the endosomal vesicle lumen into the cytosol, and acts as a zinc-dependent protease to cleave substrate specific proteins that mediate vesicle-target membrane fusion, a process that is central to neurotransmitter release.
- BoNT substrate proteins include the cell membrane protein syntaxin, peripheral membrane protein SNAP-25, and the vesicular membrane protein synaptobrevin (Syb). These proteins are collectively referred to as SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. Cleavage of SNARE proteins blocks vesicle fusion with the cell membrane and abolishes neurotransmitter release at neuromuscular junctions.
- SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor
- syntaxin and SNAP-25 usually reside on the target membrane and are thus referred to as t-SNAREs
- synaptobrevin is associated exclusively with synaptic vesicles within the synapse and is referred to as a v-SNARE.
- BoNT/A, E, and C cleave SNAP-25
- BoNT/B, D, F, and G cleave synaptobrevin (Syb) at separate and distinct sites.
- BoNT/C also cleaves syntaxin in addition to SNAP-25. Since BoNTs act as enzymes, even minute quantities can have a devastating effect on an affected individual.
- botulinum toxin is a source of food poisoning and has the potential for use as a bioterrorism weapon, there are therapeutic applications.
- botulinum toxin has been utilized to treat conditions associated with unwanted muscle contractions (such as strabismus) and in the treatment of persistent migraines. It is also widely used for cosmetic purposes, where the selective paralysis of small muscles beneath the skin temporarily reduces the appearance of age-related wrinkles.
- This process is complicated by the need to accurately quantify BoNT activity rather than simply quantify the amount of BoNT protein present, as purification processes utilized in isolating these proteins can lead to a significant degree of denaturation and resulting inactivation of these proteins.
- FRET fluorescence resonance energy transfer
- fluorescent proteins in particular Green Fluorescent Protein and variants thereof as described in International Patent Application WO2008/145301A1 (to Tasdemir and Corazza), are often used as these proteins do not require the addition of a cofactor or substrate in order to fluoresce.
- Some of these assays are capable of detecting enzymatic activity.
- 7,749,759 discloses the use of cells containing a substrate for a Clostridium toxin, where the substrate (which is expressed from a genetic construct) includes a donor fluorophore and an acceptor fluorophore separated by a peptide that is cleaved by the Clostridium toxin. Exposure to the Clostridium toxin results in cleavage of the substrate, and the subsequent separation between the donor fluorophore and the acceptor fluorophore results in changes in the observed fluorescence.
- FRET-based assays have limitations.
- the excitation spectra of the donor fluorophore and of the acceptor fluorophore frequently overlap, resulting in an inherently high background signal from the acceptor fluorophore even in the absence of FRET.
- the fluorophores may self aggregate, forming fluorophore complexes within and/or between aggregated constructs that do not dissociate on cleavage of a target site.
- the use of longer peptide sequences as cleavage sites in order to accommodate more complex enzyme binding and cleavage sites can dramatically reduce the efficiency of energy transfer between fluorophores separated by such peptide sequences.
- compositions and methods are therefore needed to provide rapid and accurate characterization of BoNTs and BoNT activities.
- the present invention provides compositions and methods for use in assays that detect botulinum neurotoxins (BoNTs) which utilize a construct that includes at least two instances of the same reporter, such as a fluorophore or chromophore.
- the construct includes an anchoring site that attaches the construct to a cell and/or vesicle membrane, which in turn provides protection of the reporter from a degradative activity in the cytosol.
- the construct also includes a cleavage site that separates the anchoring site from at least one of the reporters and also serves as a substrate for an enzyme activity (for example, protease activity). Enzyme activity at the cleavage site releases reporter from the construct; subsequent degradation of the reporters in the cytosol results in a measureable change from a baseline signal that is proportional to enzyme activity.
- Embodiments of the inventive concept include a reporting construct that can be used for characterizing an enzyme activity (for example, the activity of a botulinum neurotoxin), and cells that include a nucleic acid encoding for such a reporting construct.
- the reporting construct includes a membrane anchoring domain that interacts with a membrane of a cell (for example, a plasma membrane or a vesicle membrane), a reporter domain that includes two or more occurrences of a signal generating peptide (for example, a peptide sequence corresponding to a fluorescent protein or having at least 80% sequence identity to Green Fluorescent Protein), and a cleavage site that is located between the membrane anchoring site and the reporter domain.
- the signal generating peptides produce indistinguishable signals, and the total signal produced by the reporter domain is an aggregate of these individual yet indistinguishable signals.
- the cleavage site includes a peptide that is susceptible to cleavage by the enzyme activity (for example a SNARE protein or a fragment thereof), and such cleavage results in the release of the reporter domain into the cytoplasm.
- Such cleavage sites can be selected to be susceptible to cleavage by more than one enzyme (for example, both BoNT/A and BoNT/E).
- the reporter domain undergoes degradative events following release into the cytoplasm, with separate degradative events causing a loss of signal from each of the signal generating peptides and resulting in a gradual loss of the aggregate signal of the reporter domain.
- a linker peptide is interposed between the signal generating peptides.
- the construct can be cleaved by more than one enzyme, and shows reduced bias in regards to susceptibility of cleavage by one enzyme activity (for example BoNT/A) over a second enzyme activity (for example BoNT/E) relative to an analogous construct having a reporting domain with a single signal generating peptide.
- the reporting construct includes an auxiliary reporting domain that provides a signal that is distinguishable from that of the reporter domain.
- Another embodiment of the inventive concept is a method for characterizing an enzyme activity by providing a cell that expresses a reporting construct, contacting the cell with a sample suspected of including the enzyme activity, and observing a decrease in a signal generated by the reporting construct in the presence of the enzyme activity.
- the reporting construct includes a membrane anchoring domain that interacts with a membrane of a cell (for example, a plasma membrane or a vesicle membrane), a reporter domain that includes two or more occurrences of a signal generating peptide (for example, a peptide sequence corresponding to a fluorescent protein and/or having at least 80% sequence identity to Green Fluorescent Protein), and a cleavage site that is located between the membrane anchoring site and the reporter domain.
- a membrane anchoring domain that interacts with a membrane of a cell (for example, a plasma membrane or a vesicle membrane)
- a reporter domain that includes two or more occurrences of a signal generating peptide (for example, a peptid
- the signal generating peptides produce indistinguishable signals, such that the total signal produced by the reporter domain is an aggregate of these individual yet indistinguishable signals.
- the cleavage site includes a peptide that is susceptible to cleavage by the enzyme activity (for example a SNARE protein or a fragment thereof), and such cleavage results in the release of the reporter domain into the cytoplasm.
- the reporter domain undergoes degradative events following release into the cytoplasm, with separate degradative events causing a loss of signal from each of the signal generating peptides and resulting in a gradual loss of the aggregate signal of the reporter domain.
- the aggregate signal of the reporter domain is observable following the loss of the signal from one of the signal generating peptides from a degradative event.
- the construct can be cleaved by more than one enzyme, and shows reduced bias in regards to susceptibility of cleavage by one enzyme activity (for example BoNT/A) over a second enzyme activity (for example BoNT/E) relative to an analogous construct having a reporting domain with a single signal generating peptide.
- a reference signal is provided that is distinguishable from the signal provided by the reporter domain and can be utilized for normalization of the signal from the reporter domain of the reporting construct.
- the reference signal is provided by including an auxiliary reporter with the construct, where the auxiliary reporter produces a signal distinguishable from the reporter domain and is not affected by the enzyme activity
- the reference signal is provided by contacting the cell with a cell dye (for example a membrane dye or a nucleus/nuclear dye). Such a cell dye can be brought into contact with the cell before, during, or after contacting the cell with the enzyme activity.
- FIGS. 1A to 1D schematically depict constructs of the inventive concept and show typical results.
- FIGS. 1A to 1C schematically depict constructs of the inventive concept that have two identical reporting peptides in various configurations.
- FIG. 1D shows typical results for a cell-based assay for two different botulinum neurotoxins (BoNT/A, BoNT/E), utilizing a reporter configured as shown in FIG. 1A . Results are also shown for cells expressing an analogous construct carrying a single reporter. Surprisingly, the bias between BoNT/A and BoNT/E sensitivity is dramatically reduced in cells expressing the construct of the inventive concept.
- FIGS. 2A to 2K schematically depict constructs of the inventive concept that include two identical reporters and a third, different reporter.
- FIG. 3 depicts a cell-based assay of the invention in which the construct includes a cell membrane anchoring domain.
- FIG. 4 depicts a cell-based assay of the invention in which the construct includes a vesicle membrane anchoring domain.
- FIG. 5 shows an assay methodology of the invention.
- FIG. 6 shows an alternative assay methodology of the invention.
- FIG. 7 shows excitation and emission spectra for a fluorescent protein(eYFP) and a secondary dye
- FIG. 8 schematically depicts an assay method of the inventive concept that incorporates the use of a secondary dye.
- FIGS. 9A and 9B shows exemplary data from an assay of the inventive concept, in the absence of correction and with data normalization using a secondary dye, respectively.
- FIG. 9C shows photomicrographs produced using fluorescence and bright field microscopy of cells expressing a construct of the inventive concept, in the absence and in the presence of a corresponding botulinum toxin.
- Embodiments of the inventive concept utilize one or more cells that include a construct (for example introduced via expression following transfection and/or microinjection) that includes components that sequester an observable reporter moiety or region in a protected region and an analyte-sensitive region.
- the reporter moiety can include two or more identical reporters.
- Such protected regions can be in proximity to a cell membrane and/or a vesicle membrane.
- Interaction of the analyte sensitive region with the analyte results in the release of the reporter from the protected region by a cleavage event, which results in the degradation of the reporter and an observable change in the signal from the reporter.
- Examples of analytes can include proteolytic enzymes, and in such cases the analyte sensitive region can be a cleavage site that can serve as an enzyme substrate.
- Embodiments of the inventive concept include methods in which such constructs are expressed in cells, which are subsequently exposed to an analyte of interest (for example, a Clostridium botulinum and/or Clostridium tetani toxin). Such cells can be division arrested cells. It should be appreciated that the novel arrangement and composition of constructs of the inventive concept has a direct impact on the mechanism and performance characteristics of such assays.
- analyte of interest for example, a Clostridium botulinum and/or Clostridium tetani toxin.
- a cleavage event at an analyte sensitive region or domain of the construct, resulting in the release of a construct fragment that includes a reporter region carrying two or more identical signal generating regions (for example a pair of identical fluorophores) each of which generate a detectable signal.
- a construct fragment that includes a reporter region carrying two or more identical signal generating regions (for example a pair of identical fluorophores) each of which generate a detectable signal.
- FRET pairs for example, different fluorophores arranged as hetero-FRET pairs and/or similar or identical fluorophores arranged as homo-FRET pairs
- each of the signal generating regions of a reporter released as a construct fragment contributes directly to a detectable aggregate signal both before and immediately following the cleavage event.
- such an aggregate signal can be an approximate summation (or other function) of the signal observed from each of the signal generating regions.
- the change in the detectable signal that forms the basis of detection is a result of multiple degradation events that occur in the cytosol subsequent to the cleavage event, as loss of one of a pair of identical signal generating regions (for example, a pair of essentially identical fluorophores) still providing an emitting reporter fragment.
- a single degradation event occurring at a released construct fragment can result in fragmentation of the single reporter and loss of the detectable signal.
- constructs utilizing duplicate reporters in which the detectable signal is a result of interaction between the reporters for example, a construct utilizing a pair of fluorophores arranged to perform hetero-FRET and/or homo-FRET
- the fragmentation of a single signal generating region due to a single degradation event also results in a loss of the detectable signal from that construct.
- a reporter-containing fragment generated by a cleavage event directed to a construct of the inventive concept that is configured to release two or more identical/indistinguishable signal generating regions following the cleavage event can continue to provide a detectable signal following a single degradation event occurring at one of the occurrences of the signal generating region. Since multiple degradation events are required to halt the generation of detectable signal by the construct cleavage fragment, the detectable signal decreases with increasing analyte concentration but persists (relative to single reporter constructs or constructs that depend upon paired reporters for signal generation) at high analyte concentrations. This can result in an improved dynamic range for assays based on constructs of the inventive concept.
- a construct of the inventive concept can be arranged in a variety of ways.
- the following description includes a number of examples in which functional domains of a reporting construct, for example, a membrane anchor (A), a cleavage site (B), multiple occurrences of a primary signal generating region/reporter (C, C′), and in some instances a secondary reporter (D) are depicted as being joined in various arrangements by linker regions or linkers ( ⁇ ).
- linker regions or linkers ⁇
- linker regions of the inventive concept can also include portions of a functional region that are not directly involved in the function of that region.
- a linker can be a portion of the protein fluorophore sequence that is not directly involved in fluorescence.
- a linker can be a portion of cleavage site sequence that does not directly serve as a protease substrate.
- a linker can be a synthetic or engineered peptide sequence, which can, for example, be designed to reduce FRET (i.e. homo-FRET and/or heter-FRET) between signal generating regions to non-useful levels (for example, less than about 5%).
- Such a synthetic peptide sequence can be a flexible sequence, a rigid sequence, or a sequence with both flexible and rigid portions.
- SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9 show exemplary synthetic linker sequences.
- a linker region can include repeated occurrences of such linker sequences (for example, in a concatemer-like arrangement) to provide desired length, flexibility, and/or other desirable structural features.
- the term “linker” does not denote a cleavage site that is cleaved by an enzyme analyte, but rather a structural region that joins other functional regions of a reporting construct.
- the reporter-containing region can contain at least two instances of a primary reporter that is a fluorophore and/or a chromophore.
- two instances of a primary reporter have the same amino acid sequence.
- two instances of a primary reporter can have different compositions but have substantially similar (i.e. exhibiting greater than or equal to 80% overlap) excitation and emission spectra.
- a primary reporter can be a fluorescent protein, for example Green Fluorescent Protein (SEQ ID NO. 10) or a peptide having at least 80% sequence identity to the sequence of Green Fluorescent Protein.
- Suitable fluorescent protein fluorophores include Yellow Fluorescent Protein (for example eYFP, SEQ ID NO.
- Red Fluorescent Protein Cyan Fluorescent Protein (SEQ ID NO. 12), mBanana, mStrawberry, mCherry, tdTomato, J-Red, DsRed monomer, mCitrine, Venus (SEQ ID NO. 13), YPet protein, Emerald, EGFP, CyPet, mCFPm, Cerulean, mPlum, mOrange, mKO, T-Sapphire, a derivative of Yellow Fluorescent Protein, a derivative of mCitrine, a derivative of Venus, a derivative of YPet protein, and/or a Green Fluorescent Protein variant.
- a primary reporter can be a monomeric fluorescent protein derived from the Green Fluorescent Protein of Aequorea victoria, such as Sirius, Azurite, EBFP2, TagBFP, mTurqoise, ECFP, Cerulean, TagCFP, mTFP1, mUkG1, mAG1, AcGFP1, TagGFP2, EDFP, mWasabi, EmGFP, TagYFP, eYFP (SEQ ID NO.
- Green Fluorescent Protein of Aequorea victoria such as Sirius, Azurite, EBFP2, TagBFP, mTurqoise, ECFP, Cerulean, TagCFP, mTFP1, mUkG1, mAG1, AcGFP1, TagGFP2, EDFP, mWasabi, EmGFP, TagYFP, eYFP (SEQ ID NO.
- suitable primary reporters can be protein fluorophores derived from the Green Fluorescent Protein of Aequorea victoria that include an A206K mutation.
- a primary reporter can be a non-fluorophore and/or a non-chromophore, for example a fluorescence quencher.
- the arrangement of primary reporters within the reporter containing portion can be such that they are sufficiently distant from one another and/or oriented such that they exhibit essentially no useful (i.e. less than 5%) FRET (for example, homo-FRET) energy transfer.
- Contemplated low levels of homo-FRET energy transfer can be less than or equal to about 1%, less than or equal to about 0.1%, less than or equal to about 0.01%, and/or less than or equal to about 0.001% energy transfer between fluors.
- contemplated low levels of homo-FRET energy transfer can be less than or equal to about 10%, less than or equal to about 1%, less than or equal to about 0.1%, less than or equal to about 0.01%, and/or less than or equal to about 0.001% of the background noise of the observable signal.
- the primary reporters 120 , 130 can be arranged such that they exhibit significant (i.e. greater than about 1%) homo-FRET energy transfer.
- Such phenomena can be controlled using the length of a linker region or linker interposed between such primary reporters.
- such a linker can have a length of 20, 30, 40 50, or more amino acids.
- the such a linker can have a linear dimension of at least about 4, about 6, about 8, about 10, about 15, about 20 or more nanometers when the construct is in its native, folded state.
- a primary reporter of a construct of the inventive concept can include more than one fluorescent moiety.
- a pair of fluorophores with different but overlapping excitation and emission spectra could be arranged as a FRET pair that acts as a single instance of a primary reporter.
- a pair of identical fluorophores could be arranged as a homo-FRET pair that acts as a single instance of a primary reporter (for instance, as detected by fluorescence anisotropy).
- a reporting construct could include a pair of primary fluorophores, where each primary fluorophore includes two fluorophores with different but overlapping excitation and emission spectra arranged as a hetero-FRET pair.
- a reporting construct could include a pair of primary fluorophores, where each primary fluorophore includes two fluorophores with similar or identical excitation and emission spectra arranged as a homo-FRET pair.
- Such a reporter construct can include a membrane anchor 170 that is linked to a cleavage site 160 by an interposing anchor/cleavage site linker 150 .
- the cleavage site is in turn linked to a first instance of a pair of identical primary reporters 120 by a cleavage site/reporter linker 165 .
- This first instance of a pair of identical primary reporters 120 is linked to a second instance of a pair of identical primary reporters 130 by an interposing primary reporter/primary reporter linker 140 .
- the reporter-containing region can contain at least two instances of a primary reporter.
- An example of a reporter construct having such a structure is shown in SEQ ID NO 14 .
- FIG. 1B An alternative arrangement of the reporter construct (which can be characterized as A-C-B-C′) is shown schematically in FIG. 1B , in which a membrane anchor 170 is linked to a first instance of a pair of identical primary reporters 120 by an interposing anchor/primary reporter linker 125 .
- the first instance of a pair of identical primary reporters 120 is linked to a cleavage site 160 via a first cleavage site/fluor linker 165 A.
- the cleavage site 160 is also linked to a second instance of a pair of identical primary reporters 130 via a second cleavage site/fluor linker 165 B. Emission from such a retained reporter 120 can, for example, be used as a baseline or normalizing signal.
- FIG. 1C Another alternative arrangement of the reporter construct (which can be characterized as C-A-B-C′) is shown in FIG. 1C , in which a first instance of a pair of identical primary reporters 120 is linked to a membrane anchor portion 170 by an intervening anchor/primary reporter linker 125 .
- the membrane anchor 170 is also linked to a cleavage site 160 by an anchor/cleavage site linker 150 .
- the cleavage site is 160 is, in turn, linked to a second instance of a pair of identical primary reporters 130 via a cleavage site/reporter linker 165 .
- Emission from such a retained reporter 120 can, for example, be used as a baseline or normalizing signal.
- the reporter linker 140 can be placed on either side of the cleavage site 160 in such an embodiment.
- hydrolysis of the cleavage site 160 results in the release of one or more primary reporters 120 , 130 from the membrane anchoring domain 170 .
- the cleavage site therefore, at least partially determines the specificity of assays based upon such constructs for specific enzyme activities, and preferably includes hydrolysis sites where enzyme activity results in cleavage of the peptide backbone of the construct and recognition sites that provide interaction sites with the enzyme and confer at least a portion of substrate specificity.
- the cleavage site can include regions that interact with exosites or allosteric sites of a target enzyme.
- the cleavage site is susceptible to cleavage by a Botulinum neurotoxin BoNT protease activity, for example BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, and/or BoNT/G.
- a cleavage site sequence can be selected or designed to provide cleavage and recognition sites for two or more different BoNTs (for example, both BoNT/A and BoNT/E).
- the cleavage site can include intact sequences or sequences derived from a SNARE protein, such as a synaptosomal-associated protein (for example, SNAP-25; SEQ ID NO.
- a vesicle associated membrane protein for example, VAMP or synaptobrevin; SEQ ID NO. 11
- sequences derived from a syntaxin examples include SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, and SEQ ID NO. 18.
- release from a membrane anchoring domain can permit one or more primary reporters to diffuse away from a protected region.
- protected regions can include proximity to a cell membrane and/or to a vesicle membrane.
- an anchoring domain can include a cell membrane localizing peptide and/or a vesicle membrane localizing peptide.
- Such an anchoring region can include a transmembrane region in which at least a portion of the peptide chain enters and/or passes through a membrane of the cell.
- an anchoring region can include a palmitoylation site that, following post-translational processing by the cell, provides a site that interacts with a membrane of the cell.
- a membrane anchoring site can include a peptide sequence that interacts with a membrane-bound receptor or ligand.
- an anchoring domain can include sequences derived from a synaptobrevin (for example a transmembrane peptide of synaptobrevin) and/or from SNAP-25 (for example a palmitoylation region of SNAP-25).
- a membrane anchoring domain can be a syntaxin or a syntaxin fragment.
- primary reporters can diffuse into the cytosol.
- Use of two or more primary reporters provides a number of technical advantages. Advantages of constructs that release two or more primary reporters upon cleavage are described above. Other advantages include the ability to utilize lower expression levels for the construct (thereby minimizing the risk of toxicity and/or construct aggregation) and/or the ability to utilize far fewer cells in a cell-based assay.
- the relatively strong signal generated by multiple primary reporters can provide for more stable and reproducible baseline measurements, which also serve to increase assay sensitivity by permitting more robust differentiation of signal from noise. It should be noted that previous investigators (A. G. von Armin, X. W. Deng, and M. G.
- constructs with reporting regions that include multiple primary reporters can provide different selectivity between enzyme targets compared to analogous constructs in which the reporting region contains a single occurrence of a primary reporter.
- FIG. 1D shows comparative data for the response of cell based assays to BoNT/A and to BoNT/E, where the cells include either a construct of the inventive concept that includes two eYFP protein fluorophores in an A-B-C-C′ arrangement or an analogous construct that includes a single eYFP protein fluorophore in an A-B-C arrangement.
- BoNT/A and BoNT/E recognize and cleave the cleavage site of both constructs, however the single fluorophore construct has an approximately 80-fold bias (i.e. approximately 80-fold better sensitivity, as expressed in terms of EC 50 ) for the BoNT/A neurotoxin over the BoNT/E neurotoxin (see FIG. 1D , 37° C.).
- the same study performed using cells expressing the “dual fluorophore” reporting construct i.e. the construct carrying two eYFP fluorophores
- a reporter construct can include, in addition to two or more primary reporters, a secondary reporter that differs from the primary reporters.
- the secondary reporter can have a distinct or different chemical structure from that of the primary reporters.
- Such a secondary reporter can have an emission spectrum that overlaps the excitation spectrum of a primary reporter.
- the construct can be arranged so that significant FRET (i.e. greater than about 1%) occurs between a secondary reporter and a primary reporter.
- the secondary reporter is a fluorescent protein, such as Yellow Fluorescent Protein, Red Fluorescent Protein, Cyano Fluorescent Protein, Green Fluorescent Protein, mBanana, mStrawberry, mCherry, tdTomato, J-Red, DsRed monomer, mCitrine, Venus, YPet protein, Emerald, EGFP, CyPet, mCFPm, Cerulean, mPlum, mOrange, mKO, T-Sapphire, a derivative of Yellow Fluorescent Protein, a derivative of mCitrine, a derivative of Venus, a derivative of YPet protein, and/or a Green Fluorescent Protein variant.
- a fluorescent protein such as Yellow Fluorescent Protein, Red Fluorescent Protein, Cyano Fluorescent Protein, Green Fluorescent Protein, mBanana, mStrawberry, mCherry, mCherry, tdTomato, J-Red, D
- the reporter construct can be arranges such that significant or useful FRET does not occur (i.e. the degree of FRET that occurs is less than or equal to 5%) between the secondary reporter and a primary reporter.
- the arrangement of the secondary reporter and at least one of the primary reporters within the reporter construct can be such that they are sufficiently distant from one another that they exhibit essentially no useful (i.e. less than or equal to 5%) FRET.
- Contemplated non-useful levels of FRET energy transfer can be less than or equal to about 10%, less than or equal to about 5%, less than or equal to about 1%, or less than or equal to about 0.1% of the associated background fluorescence. This can be accomplished by selecting a linker that provides sufficient distance between the secondary reporter and a primary reporter.
- such a linker can have a length of 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 or more amino acids.
- the a linker between two primary reporters can have a length of at least about 4, about 6, about 8, about 10, about 15, about 20 or more nanometers when the construct is in its native, folded state.
- Suitable linkers can include synthetic peptides, and such peptides can be flexible peptides, rigid peptides, or can include both flexible and rigid portions.
- a signal or emission from a secondary reporter can be utilized as a reference or as normalization data useful for adjusting or normalizing a signal observed from one or more reporters of the reporter-containing portion, thereby improving precision and/or sensitivity of an assay utilizing such a construct.
- a signal or emission from a secondary reporter can be utilized by an image recognition system to identify the location within an acquired image wherein a reaction of the assay can be taking place, thereby simplifying data acquisition.
- FIG. 2A An example of an embodiment that includes such a secondary reporter (which can be characterized as having the structure A-D-B-C-C′, where “D” represents the secondary reporter) is shown schematically in FIG. 2A .
- a membrane anchor 270 is linked to a secondary reporter 280 by an intervening anchor/secondary reporter linker 285 .
- the secondary reporter 280 is also linked to a cleavage site 260 by a secondary reporter/cleavage site linker 255 .
- the cleavage site 260 is, in turn, linked to a first instance of a pair of identical primary reporters 220 via a cleavage site/primary reporter linker 265 , and the first instance of a pair of identical primary reporters 220 and the second instance of a pair of identical primary reporters 230 are joined by an intervening primary reporter/primary reporter linker 240 .
- FIG. 2B An alternative embodiment of a reporting construct with two or more primary reporters and at least one secondary reporter (which can be described as D-A-B-C-C′) is depicted schematically in FIG. 2B .
- a secondary reporter 280 is coupled to a membrane anchor 270 by an intervening anchor/secondary reporter linker 285 .
- the membrane anchor 270 is in turn linked to a cleavage site 260 by an anchor/cleavage site linker 250 .
- the pair of identical primary reporters 220 , 230 which are joined by a primary reporter/primary reporter linker 240 are in turn attached to the cleavage site 260 via a cleavage site/primary reporter linker 265 .
- FIG. 2C schematically depicts an embodiment of a reporting construct (which can be described as C-D-A-B-C′) in which a first instance of a pair of identical primary reporters 220 is joined to a secondary reporter 280 by a primary reporter/secondary reporter linker 275 .
- the secondary reporter 280 is in turn coupled to a membrane anchor 270 by an intervening anchor/secondary reporter linker 275 .
- the membrane anchor 270 is further joined to a cleavage site 260 , with an anchor/cleavage site linker 250 interposed between them.
- a second instance of a pair of identical primary reporters 230 is also coupled to the cleavage site 260 by a cleavage site/primary reporter linker 265 .
- FIG. 2D schematically depicts an embodiment of a reporting construct (which can be described as D-C-A-B-C′) in which a secondary reporter 280 is joined to a first instance of a pair of identical primary reporters 220 by a primary reporter/secondary reporter linker 275 .
- the first instance of a pair of identical primary reporters 220 is in turn coupled to membrane anchor 270 , with an anchor/primary reporter linker 245 interposed between them.
- the membrane anchor 270 is also joined to a cleavage site 260 by an anchor/cleavage site linker 250 .
- a second instance of a pair of identical primary reporters 230 is coupled to the cleavage site 260 by an interposing cleavage site/primary reporter linker 240 .
- FIG. 2E schematically depicts an embodiment of a reporting construct (which can be described as A-D-C-B-C′) in which a membrane anchor 270 is joined to a secondary reporter 280 via an anchor/secondary reporter linker 285 .
- the secondary reporter 280 is also coupled to a first instance of a pair of identical primary reporters 220 by an intervening primary reporter/secondary reporter linker 275 .
- the first instance of a pair of identical primary reporters 220 is in turn coupled to a cleavage site 260 by a cleavage site/primary reporter linker 265 A.
- the second instance of a pair of identical primary reporters 230 is also joined to this cleavage site 260 by another cleavage site/primary reporter linker 265 B.
- FIG. 2F schematically depicts an embodiment of a reporting construct (which can be described as A-C-D-B-C′) in which a membrane anchor 270 is joined to a first instance of a pair of identical primary reporters 220 via an interposing anchor/primary reporter linker 245 .
- a secondary reporter 280 is also coupled to the first instance of a pair of identical primary reporters 220 via a primary reporter/secondary reporter linker 275 .
- This secondary reporter 280 is linked to a cleavage site 260 by a secondary reporter/leavage site linker 255 .
- the cleavage site 260 is joined to a second instance of a pair of identical primary reporters 230 by a cleavage site/primary reporter linker 265 .
- FIG. 2G schematically depicts an embodiment of a reporting construct (which can be described as A-C-B-C′-D) in which a membrane anchor 270 is coupled to a first instance of a pair of identical primary reporters 220 by an anchor/primary reporter linker 245 .
- This first instance of a pair of identical primary reporters 220 is joined to a cleavage site 260 via a first cleavage site/primary reporter linker 265 A.
- the cleavage site 260 is also joined to a second instance of a pair of identical primary reporters 230 by a second cleavage site/primary reporter linker 265 B.
- a secondary reporter 280 is also coupled to the second instance of a pair of identical primary reporters 230 by an intervening primary reporter/secondary reporter linker 275 .
- FIG. 2H schematically depicts an embodiment of a reporting construct (which can be described as A-C-B-D-C′) in which a membrane anchor 270 is coupled to a first instance of a pair of identical primary reporters 220 by an anchor/primary reporter linker 245 .
- This first instance of a pair of identical primary reporters 220 is joined to a cleavage site 260 via a cleavage site/primary reporter linker 265 .
- the cleavage site 260 is also joined to a secondary reporter 280 by a secondary reporter/cleavage site linker 255 .
- a second instance of a pair of identical primary reporters 230 is also coupled to the secondary reporter 280 , by an intervening primary reporter/secondary reporter linker 275 .
- FIG. 2I schematically depicts an embodiment of a reporting construct (which can be described as A-B-C-D-C′) in which a membrane anchor 270 is coupled to a cleavage site 260 by an anchor/cleavage site linker 250 .
- This cleavage site 260 is joined to a first instance of a pair of identical primary reporters 220 via a cleavage site/primary reporter linker 265 .
- This first instance of a pair of identical primary reporters 220 is also joined to a secondary reporter 280 by a first primary reporter/secondary reporter linker 275 A.
- a second instance of a pair of identical primary reporters 230 is also joined to the secondary reporter 280 by a second primary reporter/secondary reporter linker 275 B.
- FIG. 2J schematically depicts an embodiment of a reporting construct (which can be described as C-A-B-D-C′) in which a first instance of a pair of identical primary reporters 220 is joined to a membrane anchor 270 by an interposing anchor/primary reporter linker 245 .
- the membrane anchor 270 is also coupled to a cleavage site 260 via an anchor/cleavage site linker 250 .
- the cleavage site 260 is subsequently linked to a secondary reporter 280 by a cleavage site/secondary reporter linker 255 .
- a second instance of a pair of identical primary reporters 230 is also linked to the secondary reporter, via a primary reporter/secondary reporter linker 275 .
- FIG. 2K schematically depicts an embodiment of a reporting construct (which can be described as C-A-B-C′-D) in which a first instance of a pair of identical primary reporters 220 is joined to a membrane anchor 270 by an interposing anchor/primary reporter linker 245 .
- the membrane anchor 270 is also coupled to a cleavage site 260 via an anchor/cleavage site linker 250 .
- the cleavage site 260 is subsequently linked to a second instance of a pair of identical primary reporters 230 by an anchor/primary reporter linker 265 .
- a secondary reporter 280 is also linked to the second instance of a pair of identical primary reporters 230 by a primary reporter/secondary reporter linker 275 .
- a primary reporter is connected to a secondary reporter by an intervening linker.
- the primary/secondary linker is selected to provide no significant (i.e. less than 5%) FRET between a primary reporter and a secondary reporter.
- a primary/secondary reporter linker can be selected to have a length, geometry, and/or rigidity to maintain a distance and/or orientation between a primary reporter and a secondary reporter to reduce FRET to a negligible (i.e. ⁇ 5%) amount.
- a primary/secondary reporter linker can be configured to provide a useful degree of FRET (i.e. >5%) between the primary reporter and a secondary reporter.
- FIG. 3 depicts a schematic of an exemplary assay 300 of the inventive concept.
- a cell with a cell membrane 310 and cytosol 315 has expressed a construct that includes a cell membrane anchoring portion 350 , a cleavage site 340 , and two identical reporters 330 , 335 .
- Anchored to the cell membrane 310 the reporters 330 , 335 produce a strong signal 360 , 365 .
- To perform the assay the cell is exposed to an enzyme activity 320 , which can act on the cleavage site 340 . Hydrolysis of the peptide backbone of the cleavage site releases the reporters into the cytosol 315 .
- degraded reporters 330 A, 335 A that produce a modified signal 370 , 375 .
- the reporters are fluorescent proteins, and the fluorescence signal from the degraded fluorescent proteins is reduced.
- FIG. 4 depicts an alternative assay 400 of the inventive concept.
- a cell with a cell membrane 410 , cytosol 415 , and a vesicle 420 has expressed a construct that includes a vesicle membrane anchoring portion 450 , a cleavage site 440 , and two reporters 430 , 435 .
- Anchored to the vesicle 420 the reporters 430 , 435 produce a strong signal 460 , 465 .
- the cell is exposed to an enzyme activity 425 , which can act on the cleavage site 440 . Hydrolysis of the cleavage site releases the reporters, resulting in release of the reporters 430 , 435 .
- degraded reporters 430 A, 435 A that produce a modified signal 470 , 475 .
- the reporters are fluorescent proteins, and the fluorescence signal from the degraded fluorescent proteins is reduced.
- assays of the inventive concept can use a variety of different testing protocols.
- One embodiment of such a testing protocol is shown in FIG. 5 .
- a cell is provided that expresses a construct of the inventive concept.
- a baseline or first signal is acquired 520 , then the cell is exposed to the enzyme activity 530 .
- a sample containing an enzyme activity (such as a BoNT) can be added to media containing the cells.
- a second signal can be detected 540 and subsequently compared to the first signal 550 .
- Such first and second signals can be instant measurements, mean measurements obtained over time, and/or rate measurements.
- FIG. 6 An alternative embodiment of a test method of the inventive concept is shown in FIG. 6 .
- a cell is provided that expresses a construct of the inventive concept.
- the cell is then exposed to the enzyme activity 620 .
- a sample containing an enzyme activity (such as a BoNT) can be added to media containing the cells.
- a baseline or first signal is detected 630 and, following a second incubation period a second signal is detected 640 and subsequently compared to the first signal 650 .
- Such first and second signals can be instant measurements, mean measurements obtained over time, and/or rate measurements.
- cells expressing constructs as described above are exposed to one or more secondary dyes (for example a cell-binding dye such as a membrane dye or a nuclear stain/dye), that are separate from the construct and which can generate signals that are independent of BoNT activity.
- secondary dyes can associate with a membrane and/or nucleus of a cell in a fashion that is independent of the presence of an analyte (for example, a BoNT or other enzyme activity), and can be used to produce a baseline or reference signal, which can be used for normalization.
- a cell expressing a construct as described above can be exposed to a dye that associates with the nucleus or plasma membrane of the cell, and in turn provides a baseline fluorescent signal.
- such a secondary dye is selected such that the emission wavelengths of the membrane dye are distinguishable from those of a reporter fluorophore of the construct expressed in the cells.
- the secondary dye can be selected so that the range of effective excitation wavelengths overlaps with those of a reporter fluorophore of the construct, permitting simultaneous excitation of both the secondary dye and the reporter fluorophore and hence simultaneous acquisition of a baseline signal and a reporter fluorophore signal.
- a secondary dye can be selected so that the range of effective excitation wavelengths does not overlap significantly with those of the reporter fluorophore, permitting selective excitation of baseline fluorescence.
- secondary dyes examples include 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI), the dye currently known as CELLMASKTM deep red plasma membrane stain, and the nucleus-staining dye currently known as HOECHST3342TM.
- DAPI dihydrochloride
- the secondary dye is selected to provide excitation and emission spectra that have little to no overlap with the excitation and emission spectra of the reporter fluorophore of the construct, such that essentially no (i.e. less than about 5%) energy transfer occurs due to FRET.
- a suitable secondary dye the dye currently known as CELLMASKTM deep red plasma membrane stain , indicated by “Cell Mask”
- Cell Mask a YFP reporter fluorophore
- suitable secondary dyes can include proteins (for example antibodies) or other macromolecules that have an affinity for the cell and have been conjugated or complexed with fluorescent or other readily detectable molecules.
- a baseline signal that is an independent measure of cell number, density, and/or distribution.
- Such a baseline signal has considerable utility in normalization of the reporter signal obtained from cells in the course of the performance of an assay of the inventive concept. For example, expressing a result of such an assay as a ratio between the measured reporter signal from a reporter construct that is responsive to the analyte or activity of interest and the measured baseline signal in the form of fluorescence from a membrane dye provides correction for variation in the intensity of the reporter signal from test site to test site due to differences in cell number, density, and/or distribution. This advantageously improves the precision of such assays, which in turn leads to an improvement in effective sensitivity. It should also be appreciated that such a baseline signal can be utilized to provide such normalization for reporter signals other than fluorescence.
- cells transformed with an expression vector encoding for a construct as described in FIG. 1A are seeded 810 into 96-well plates and incubated overnight at 37° C. with 5% CO 2 .
- the cells are stained 830 with a secondary dye. Different secondary dyes may be applied using different protocols.
- Protocol A useful for DAPI and the dye currently known as HOECHST3342TM.
- HOECHST3342TM in cell culture media is added directly to each well of the 96-well plate to give a final concentration of 1 ⁇ M DAPI or 5 ⁇ g/ml the dye currently known as HOECHST3342TM.
- Useful final concentrations of the nucleus dye range from 0.001-10 ⁇ or 0.1-50 ⁇ g/ml. Working solution concentrations may be adjusted appropriately.
- Protocol B useful for the dye currently known as CELLMASKTM deep red plasma membrane stain.
- a working solution of 0.625-10 ⁇ g/ml in Dulbecco's phosphate buffered saline is prepared (5 ⁇ g/ml is typical).
- BoNT containing cell culture media is removed from each well.
- test plates After exposure to the membrane dye, the test plates are washed with phosphate buffered saline using an automated plate washer. The plates are then read on a fluorescence microplate reader using filters with the approximate excitation and emission wavelengths for the fluorophore of the construct and the secondary dye used 840 .
- DAPI and the dye currently known as HOECHST3342TM can be characterized using an excitation wavelength of about 345 nm and an emission wavelength of about 485 nm
- CELLMASKTM deep red plasma membrane stain can be characterized using an excitation wavelength of about 650 nm and an emission wavelength of about 680 nm.
- Measurements of the fluorophore of the construct are made independently of those of the membrane dye, using excitation and emission wavelengths characteristic of the fluorophore.
- directly excited construct fluorophore emission i.e. the BoNT sensitive component
- is normalized 850 for example by dividing the emission of the construct fluorophore by the secondary dye emission (i.e. the BoNT insensitive component).
- FIGS. 9A , 9 B, and 9 C Typical results of assays performed with reporting constructs as described above in combination with secondary dyes are shown in FIGS. 9A , 9 B, and 9 C.
- FIG. 9A shows typical uncorrected results from contacting cells containing a reporting construct with a protease (in this example, the protease is BoNT/A and the construct includes a cleavage site for BoNT/A.
- the limit of detection (LOD) in this instance is 10 pM BoNT/A, and the limit of quantitation (LOQ) is 100 pM.
- FIG. 9B shows the impact of normalization of the fluorescence data from FIG. 9A using emission data from a secondary dye applied to the same cells as described in the above procedure. The LOD for the data shown in FIG.
- FIG. 9C shows photomicrographs of two wells containing cells having BoNT/A responsive constructs by (from left to right) brightfield, fluorescence microscopy at the emission wavelength of a fluorophore of the construct, and fluorescence microscopy at the emission wavelength of the secondary dye applied to the cells.
- the well in the upper series of photomicrographs was not exposed to BoNT/A; the well in the lower series of photomicrographs was exposed to 1 nM BoNT/A.
- the loss of fluorescence from the fluorophore of the construct is evident in the 1 nM BoNT/A well (i.e. the lower series).
- emission from the secondary dye is maintained at a similar, albeit distinct and different, level and distribution from that of the well that was not exposed to BoNT/A (i.e. the upper series)
- the secondary dyes can be applied prior to contacting the cells with the BoNT, essentially simultaneously with contacting the cells with the BoNT, or at a time interval of less than 48 hours following contacting the cells with the BoNT.
- additional wash steps prior to and following exposure of the cells to the secondary dyes are contemplated.
- assays of the inventive concept rely on straightforward fluorescence measurements of fluid volumes rather than imaging and/or analysis of individual cells. As such they can be performed using a simple fluorometer (for example, a microplate fluorometer) and are advantageously highly amenable to adaptation to automation and high throughput screening processes. Data analysis is similarly straightforward, as it does not involve processor-intensive image processing tasks such as cell enumeration, identification of individual cells, and the identification of fluorescence localized in specific subcellular regions or compartments.
- such secondary dyes can serve other purposes.
- a baseline signal value can be established below which cell numbers are considered insufficient to provide an accurate assay result, permitting data from such a test site to be flagged or discarded.
- a baseline signal value can be established above which cell numbers are considered too high to provide an accurate assay result (for example, due to optical limitations in systems utilized to characterize fluorescence).
- inclusion of such secondary dyes with specific reagents that are added during the course of an assay can also be used to verify that such reagents were actually delivered to a test site during the assay process, for example to verify that automated assay systems are performing properly.
- a BoNT can be defined as a native or modified BoNT that is capable of cleaving a SNARE protein sequence or a portion of a SNARE protein sequence.
- BoNT/A, E, and C cleave SNAP-25 and BoNT/B, D, F, G cleaves synaptobrevin (Syb), at single but different sites.
- BoNT/C also cleaves syntaxin in addition to SNAP-25.
- constructs for the characterization of BoNT/A, E, and C can include cleavage sites sequences that include all or a portion of SNAP-25.
- constructs for the characterization of BoNT B, D, F, and G can include cleavage sites sequences that include all or portions of the respective susceptible regions of synaptobrevin.
- BoNT/C activity could be characterized utilizing constructs that include cleavage sites with sequences derived from all or part of syntaxin.
- Contemplated cleavage site sequences can advantageously comprise a SNARE protein, motif, or mutein.
- “Muteins” of a protein should be interpreted herein as having at least 30% identity with a corresponding native protein, including for example compositions having at least 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98% identity with the native protein. Variations from identity can comprise any or more of additions, deletions and substitutions.
- Contemplated muteins include fragments, truncates and fusion proteins.
- cells of the inventive concept can be modified to express two or more constructs.
- constructs could, for example, be distinguished by the emission spectra of their respective reporters and provide essentially independent and simultaneous measurements of different enzyme activities.
- constructs could measure the activities of the same enzyme with different substrate sequences.
- a first construct could include a cleavage site derived from SNAP-25 and a second construct could include a cleavage site derived from syntaxin, with both being used for characterizing BoNT/C activity.
- comparison of the results from both constructs can improve accuracy, dynamic range, and/or specificity.
- kits that incorporates a secondary reporter.
- a kit can contain cells that express an appropriate detecting construct, as described above, and a secondary dye (for example, a membrane dye).
- a secondary dye for example, a membrane dye
- such a kit can include directions for a user to perform the assay.
- such a kit can include control or calibration materials that include a suitable cell culture media and an enzyme activity corresponding to the enzyme activity of the sample to be characterized.
- a control sample is understood to be a sample used to verify assay performance
- a calibration sample is understood to be a sample used to calibrate the output of an assay to provide a quantitative or qualitative result.
- control and/or calibration samples could include a corresponding BoNT.
- control and/or calibration samples can be provided pre-mixed and essentially ready for use.
- control and/or calibrator samples can be provided as a first container of a suitable culture media and a second container of a stock solution of the enzyme activity.
- the first and second containers may require different shipping and/or storage conditions, and as such may be shipped and/or stored separately while remaining part of the same kit.
- inventions of the inventive concept include cell-free assays utilizing the constructs described above.
- Such an assay could, for example, utilize a cell-free vesicle suspension in which vesicles that carry one or more sites suitable for interacting with a membrane anchoring portion of a construct.
- Such vesicles, along with a construct of the inventive concept can be suspended in a medium that includes a protease or similar enzyme capable of hydrolyzing a reporter, such that cleavage of a linker portion of the construct would release reporters into the media for hydrolysis.
- sites recognized by an anchoring portion of a construct can be linked to an appropriately sized microparticle with a suitable surface chemistry.
- microparticles can carry steric blockers, for example high molecular weight dextrans or polyacrylates, that permit Botulinum toxins to access the microparticle surface while hindering the access of proteases or similar enzymes.
- steric blockers for example high molecular weight dextrans or polyacrylates, that permit Botulinum toxins to access the microparticle surface while hindering the access of proteases or similar enzymes.
- proteases or similar enzymes can be provided in high molecular weight forms (for example, as polymers or as conjugates of high molecular weight molecules) in order to enhance such selectivity.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/523,712 US20150118701A1 (en) | 2013-10-25 | 2014-10-24 | Enzyme assay with duplicate fluorophores |
US16/784,121 US11685945B2 (en) | 2013-10-25 | 2020-02-06 | Enzyme assay with duplicate fluorophores |
US18/199,056 US20240117408A1 (en) | 2013-10-25 | 2023-05-18 | Cell For Use in Enzyme Assays |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361895533P | 2013-10-25 | 2013-10-25 | |
US201361897352P | 2013-10-30 | 2013-10-30 | |
US201462014586P | 2014-06-19 | 2014-06-19 | |
US201462058532P | 2014-10-01 | 2014-10-01 | |
US14/523,712 US20150118701A1 (en) | 2013-10-25 | 2014-10-24 | Enzyme assay with duplicate fluorophores |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/784,121 Division US11685945B2 (en) | 2013-10-25 | 2020-02-06 | Enzyme assay with duplicate fluorophores |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150118701A1 true US20150118701A1 (en) | 2015-04-30 |
Family
ID=52001049
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/523,712 Abandoned US20150118701A1 (en) | 2013-10-25 | 2014-10-24 | Enzyme assay with duplicate fluorophores |
US16/784,121 Active US11685945B2 (en) | 2013-10-25 | 2020-02-06 | Enzyme assay with duplicate fluorophores |
US18/199,056 Pending US20240117408A1 (en) | 2013-10-25 | 2023-05-18 | Cell For Use in Enzyme Assays |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/784,121 Active US11685945B2 (en) | 2013-10-25 | 2020-02-06 | Enzyme assay with duplicate fluorophores |
US18/199,056 Pending US20240117408A1 (en) | 2013-10-25 | 2023-05-18 | Cell For Use in Enzyme Assays |
Country Status (13)
Country | Link |
---|---|
US (3) | US20150118701A1 (de) |
EP (2) | EP3404112B1 (de) |
JP (2) | JP6636919B2 (de) |
KR (1) | KR20160103977A (de) |
CN (2) | CN106414763B (de) |
AU (1) | AU2014339884B2 (de) |
CA (1) | CA2928609C (de) |
ES (2) | ES2686141T3 (de) |
LT (2) | LT3060677T (de) |
MX (2) | MX2016005270A (de) |
RU (1) | RU2683207C2 (de) |
TW (1) | TWI647237B (de) |
WO (1) | WO2015061738A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441640B2 (en) * | 2014-08-12 | 2019-10-15 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specificity and methods for producing same |
US12019066B2 (en) * | 2016-05-16 | 2024-06-25 | Biomadison, Inc. | Assay with synaptobrevin based moiety |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3270162T (lt) * | 2013-08-09 | 2020-09-10 | Biomadison, Inc. | Padidinto jautrumo botulino toksino tyrimas |
EP3404112B1 (de) * | 2013-10-25 | 2020-08-26 | BioMadison, Inc. | Enzymassay mit doppelten fluorophoren |
US11396499B2 (en) | 2018-12-12 | 2022-07-26 | University Of Washington | Lysosomal acid lipase assay |
TW202248635A (zh) * | 2021-04-06 | 2022-12-16 | 美商伯克利之光生命科技公司 | 微流體分析與來自非哺乳動物細胞之生物生產的方法及用於其之套組 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1131471B1 (de) * | 1998-10-30 | 2002-10-02 | Cellomics, Inc. | Ein screeningsystem auf zellbasis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048174A2 (en) | 2000-12-15 | 2002-06-20 | Stratagene | Dimeric fluorescent polypeptides |
US7183066B2 (en) * | 2002-09-27 | 2007-02-27 | Allergan, Inc. | Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins |
EP2502930B1 (de) * | 2003-12-19 | 2016-06-29 | Wisconsin Alumni Research Foundation | Verfahren und zusammensetzungen zum nachweis von botulinum-neurotoxin |
ES2351942T3 (es) * | 2005-04-05 | 2011-02-14 | Allergan Inc | Analisis de la actividad de una toxina clostridial. |
EP1997885A1 (de) | 2007-05-29 | 2008-12-03 | AXXAM S.p.A. | Floureszierende Proteine und deren Verwendung |
US8753831B2 (en) * | 2007-06-05 | 2014-06-17 | City Of Hope | Methods for detection of botulinum neurotoxin |
EP2568285B1 (de) * | 2009-03-13 | 2019-12-25 | Allergan, Inc. | Immunobasierte neu ausgerichtete endopeptidaseaktivitätstests |
ES2576747T3 (es) * | 2009-10-16 | 2016-07-11 | Biomadison, Inc. | Ensayo de transferencia de energía de resonancia con un resto de sustrato de sinaptobrevina |
BR112013030964B1 (pt) * | 2011-06-01 | 2022-08-16 | Biomadison, Inc | Ensaio botulínico de não fret |
LT3270162T (lt) | 2013-08-09 | 2020-09-10 | Biomadison, Inc. | Padidinto jautrumo botulino toksino tyrimas |
EP3404112B1 (de) * | 2013-10-25 | 2020-08-26 | BioMadison, Inc. | Enzymassay mit doppelten fluorophoren |
-
2014
- 2014-10-24 EP EP18176287.3A patent/EP3404112B1/de active Active
- 2014-10-24 MX MX2016005270A patent/MX2016005270A/es active IP Right Grant
- 2014-10-24 KR KR1020167013790A patent/KR20160103977A/ko active IP Right Grant
- 2014-10-24 LT LTEP14805702.9T patent/LT3060677T/lt unknown
- 2014-10-24 WO PCT/US2014/062260 patent/WO2015061738A1/en active Application Filing
- 2014-10-24 CN CN201480067579.1A patent/CN106414763B/zh active Active
- 2014-10-24 JP JP2016526209A patent/JP6636919B2/ja active Active
- 2014-10-24 US US14/523,712 patent/US20150118701A1/en not_active Abandoned
- 2014-10-24 LT LTEP18176287.3T patent/LT3404112T/lt unknown
- 2014-10-24 CA CA2928609A patent/CA2928609C/en active Active
- 2014-10-24 ES ES14805702.9T patent/ES2686141T3/es active Active
- 2014-10-24 EP EP14805702.9A patent/EP3060677B1/de active Active
- 2014-10-24 RU RU2016118286A patent/RU2683207C2/ru active
- 2014-10-24 CN CN202110296502.3A patent/CN113073129A/zh active Pending
- 2014-10-24 AU AU2014339884A patent/AU2014339884B2/en active Active
- 2014-10-24 ES ES18176287T patent/ES2829612T3/es active Active
- 2014-10-27 TW TW103137023A patent/TWI647237B/zh active
-
2016
- 2016-04-22 MX MX2019013952A patent/MX2019013952A/es unknown
-
2019
- 2019-12-19 JP JP2019229224A patent/JP2020062032A/ja active Pending
-
2020
- 2020-02-06 US US16/784,121 patent/US11685945B2/en active Active
-
2023
- 2023-05-18 US US18/199,056 patent/US20240117408A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1131471B1 (de) * | 1998-10-30 | 2002-10-02 | Cellomics, Inc. | Ein screeningsystem auf zellbasis |
Non-Patent Citations (2)
Title |
---|
Arai et al, Design of the linkers which effectively separate domains of a bifunctional fusion protein.Protein Eng. 2001 Aug;14(8):529-32. * |
Washbourne et al, Botulinum neurotoxin types A and E require the SNARE motif in SNAP-25 for proteolysis. FEBS Letters 418 (1997) 1-5. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10441640B2 (en) * | 2014-08-12 | 2019-10-15 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specificity and methods for producing same |
US11357838B2 (en) | 2014-08-12 | 2022-06-14 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specificity and methods for producing same |
US12019066B2 (en) * | 2016-05-16 | 2024-06-25 | Biomadison, Inc. | Assay with synaptobrevin based moiety |
Also Published As
Publication number | Publication date |
---|---|
KR20160103977A (ko) | 2016-09-02 |
RU2016118286A3 (de) | 2018-05-21 |
AU2014339884A1 (en) | 2016-05-12 |
US20210032675A1 (en) | 2021-02-04 |
CA2928609C (en) | 2022-03-15 |
LT3404112T (lt) | 2020-12-28 |
WO2015061738A4 (en) | 2015-07-02 |
CA2928609A1 (en) | 2015-04-30 |
JP6636919B2 (ja) | 2020-01-29 |
MX2016005270A (es) | 2017-02-02 |
ES2686141T3 (es) | 2018-10-16 |
JP2020062032A (ja) | 2020-04-23 |
WO2015061738A1 (en) | 2015-04-30 |
TWI647237B (zh) | 2019-01-11 |
ES2829612T3 (es) | 2021-06-01 |
EP3060677A1 (de) | 2016-08-31 |
TW201531481A (zh) | 2015-08-16 |
US11685945B2 (en) | 2023-06-27 |
RU2683207C2 (ru) | 2019-03-26 |
EP3404112B1 (de) | 2020-08-26 |
US20240117408A1 (en) | 2024-04-11 |
CN113073129A (zh) | 2021-07-06 |
JP2016533733A (ja) | 2016-11-04 |
EP3404112A1 (de) | 2018-11-21 |
MX2019013952A (es) | 2020-01-30 |
EP3060677B1 (de) | 2018-07-04 |
LT3060677T (lt) | 2018-08-27 |
RU2016118286A (ru) | 2017-11-30 |
CN106414763B (zh) | 2021-04-09 |
AU2014339884B2 (en) | 2020-03-05 |
CN106414763A (zh) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11685945B2 (en) | Enzyme assay with duplicate fluorophores | |
EP2715355B1 (de) | Nicht auf "fret" beruhender botulismusassay | |
EP3030905B2 (de) | Botulinumtoxin-assay mit erhöhter empfindlichkeit | |
US20220196634A1 (en) | Assay with Synaptobrevin Based Moiety | |
US12019066B2 (en) | Assay with synaptobrevin based moiety | |
KR102059091B1 (ko) | 보툴리눔 분석 감도를 증진시키기 위한 방법 및 화합물 | |
WO2023205355A1 (en) | Cell based assays for botulinum neurotoxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOMADISON, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TUCKER, WARD C.;REEL/FRAME:036794/0166 Effective date: 20141117 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |